Table 1: Demographic Data for Flow Cytometry Cohort.

B cell phenotyping was performed on a cohort of 26 SLE and 6 healthy donors. * Of those on systemic steroids, mean±SD prednisone-equivalent dose was 10.2±11.8mg (range 2.5–25mg). Patients on B cell depletion therapy (rituximab) were excluded.

	SLE (n = 26)	Healthy (n = 6)
Age (mean±SD, range)	42.8±13.8 (19 to 69)	51.7±7.7 (38 to 58)
Sex	88.6% Female	83.3% Female
Race	38.5% African American 53.9% Caucasian 7.6% Other	83.3% Caucasian 16.7% African American
Ethnicity	11.5% Hispanic 88.5% Non-Hispanic	100% Non-Hispanic
SLEDAI (mean±SD, range)	3.2±3.0 (0–10)	--
% Active (SLEDAI≥6)	23%	--
ANA (mean±SD, range)	1:809 (1:80–1:2560)	--
dsDNA (mean±SD, range)	706±2443 (0–9523)	--
Therapy	92.3% Hydroxychloroquine 42.3% Systemic Steroids* 19.2% Belimumab 19.2% Azathioprine 19.2% Mycophenolate Mofetil 7.7% Tacrolimus 3.8% Quinacrine 3.8% Methotrexate	--